Key result
An annual height loss of ≥0.6 cm/year was independently associated with a 25% increased risk of major adverse cardiovascular and cerebral events compared to minimal height loss (HR 1.25).
Why the study?
The association between height loss and cardio-/cerebrovascular disease incidence was not clearly established.
Does height loss increase the incidence of cardio-/cerebrovascular disease in the Korean population?
Cohort (n=127,573)
Does height loss increase the incidence of cardio-/cerebrovascular disease in the Korean population?
A greater degree of height loss is independently associated with an increased risk of major adverse cardiac and cerebrovascular events.
Answers are grounded in this paper and cite their sources.
Height loss may signal higher MACCE risk; hypothesis-generating and should not yet change practice.
Question: What is the association between height loss and cardio-/cerebrovascular disease (CVD) incidence? Method: The data we obtained is a sample cohort data provided by NHIS from 2002 to 2015. The chi-square test and the Kruskal-Wallis test were used to see the group differences in demographic characteristics. To compute the primary and secondary outcomes, we used the Cox proportional-hazard model, Kaplan-Meier survival curve, and logistic regression. Results: The cumulative MACCE incidence rate was 3.6 % for Group 1, 4.5 % for Group 2, and 5.2 % for Group 3. Group 3 had a significantly higher incidence of MACCE than Group 1 (Group 1: hazard ratio [HR] = 1.46, 95 % confidence interval [CI] = 1.32-1.62; Group 2: HR = 1.27, 95 % CI = 1.17-1.37). In the model adjusted for age, sex, comorbidities, income level, body mass index, smoking, and drinking status, the MACCE risk was 1.25 times higher in Group 3 than Group 1 (95 % CI = 1.13-1.40). Conclusion: The degree of height loss was independently associated with CVD occurrences in the Korean population.
No takes yet. Share an insight, caveat, or question.
Moon et al. (2021) conducted a cohort in Cardiovascular disease (n=127,573). Height loss ≥ 0.6 cm/year vs. Height loss 0 to < 0.3 cm/year was evaluated on Major adverse cardiac and cerebral events (MACCE) (HR 1.25, 95% CI 1.13-1.40, p=<0.0001). An annual height loss of ≥0.6 cm/year was independently associated with a 25% increased risk of major adverse cardiovascular and cerebral events compared to minimal height loss (HR 1.25).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: